Show simple item record

dc.contributor.authorArmstrong, Anne C
dc.contributor.authorClay, Vanessa
dc.date.accessioned2019-09-11T09:09:20Z
dc.date.available2019-09-11T09:09:20Z
dc.date.issued2019en
dc.identifier.citationArmstrong AC, Clay V. Olaparib in germline-mutated metastatic breast cancer: implications of the OlympiAD trial. Future Oncol. 2019;15(20):2327-35.en
dc.identifier.pmid31304797en
dc.identifier.doi10.2217/fon-2018-0067en
dc.identifier.urihttp://hdl.handle.net/10541/622050
dc.description.abstractBreast cancer remains a leading cause of death worldwide. Our increased understanding of cellular mechanisms inherent to cancer has led to the development of new therapeutic targets. One such therapy is that of poly(ADP-ribose) polymerase (PARP) inhibitors, with PARP playing a key role in the repair of single stranded DNA breaks. The development of drugs able to inhibit PARP led to their investigation in tumors that have defective DNA repair, including that of BRCA1/2-associated cancers. The PARP inhibitor Olaparib, has recently been evaluated in the Phase III OlympiAD trial, and demonstrated a significant progression-free survival advantage in patients with HER2-negative metastatic breast cancer and a germline BRCA-mutatioN This article will review the findings and potential implications of the trial.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.2217/fon-2018-0067en
dc.titleOlaparib in germline-mutated metastatic breast cancer: implications of the OlympiAD trialen
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Road Manchester M20 4BX, UKen
dc.identifier.journalFuture Oncologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record